Apheris
CompanyAI is fundamentally dependent on data, but the vast majority of health data goes unused for understandable reasons — chiefly patient privacy, regulation, and IP protection. “This is the core underlying problem” of building AI solutions for life sciences and related areas like pharmaceutics, said German entrepreneur Robin Röhm.
Date
Jan 2, 2025
Category
devtools
Lead investor
OTB Ventures
Stage
Series A
Size
$20.8M
Greycroft
General Catalyst
Index Ventures
Highland Europe
Avenir
Founders Fund
Matrix Partners
Notable Capital
Sequoia